drugset / Trial / NCT01069094

A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

NCT01069094

Phase 1/2 Completed 29 enrolled Repros Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study of 3 doses of Progenta versus placebo versus Lucron Depot for treatment of leiomyomata.

Timeline

Start
2004-07
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lucron Depot Unknown 3.75 mg Intramuscular
Subject Telapristone Acetate Other / unclassified 12.5 mg Oral
Subject Telapristone Acetate Other / unclassified 25 mg Oral
Subject Telapristone Acetate Other / unclassified 50 mg Oral

Indications